Pan Xue-Lin, Li Hong-Jun, Li Zhen, Li Zhen-Lin
Department of Radiology, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China.
West China Hospital of Medicine, Sichuan University, Chengdu 610041, Sichuan Province, China.
World J Clin Cases. 2022 Jul 16;10(20):6927-6935. doi: 10.12998/wjcc.v10.i20.6927.
The prognostic role of the skeletal muscle mass index (SMI) derived from computed tomography (CT) imaging been well verified in several types of cancers. However, whether the SMI could serve as a reliable and valuable predictor of long-term survival in lung cancer patients remains unclear.
To identify the prognostic value of the CT-derived SMI in lung cancer patients.
The PubMed, Web of Science, and Embase electronic databases were searched up to November 5, 2021 for relevant studies. The Reference Citation Analysis databases were used during the literature searching and selection. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to assess the association of the SMI with the overall survival (OS) of lung cancer patients. All statistical analyses were performed with STATA 12.0 software.
A total of 12 studies involving 3002 patients were included. The pooled results demonstrated that a lower SMI was significantly related to poorer OS (HR = 1.23, 95%CI: 1.11-1.37, < 0.001). In addition, the subgroup analyses stratified by treatment (nonsurgery surgery), tumor stage (advanced stage early stage), and tumor type (non-small cell lung cancer lung cancer) showed similar results.
The CT-derived SMI is a novel and valuable prognostic indicator in lung cancer and might contribute to the clinical management and treatment of lung cancer patients.
源自计算机断层扫描（CT）成像的骨骼肌质量指数（SMI）的预后作用已在多种癌症中得到充分验证。然而，SMI是否可作为肺癌患者长期生存的可靠且有价值的预测指标仍不清楚。
确定CT衍生的SMI在肺癌患者中的预后价值。
检索截至2021年11月5日的PubMed、Web of Science和Embase电子数据库以查找相关研究。在文献检索和筛选过程中使用了参考文献分析数据库。计算风险比（HR）和95%置信区间（CI）以评估SMI与肺癌患者总生存期（OS）的关联。所有统计分析均使用STATA 12.0软件进行。
共纳入12项研究，涉及3002例患者。汇总结果表明，较低的SMI与较差的OS显著相关（HR = 1.23，95%CI：1.11 - 1.37，P < 0.001）。此外，按治疗（非手术 手术）、肿瘤分期（晚期 早期）和肿瘤类型（非小细胞肺癌 肺癌）分层的亚组分析显示了相似的结果。
CT衍生的SMI是肺癌中一种新颖且有价值的预后指标，可能有助于肺癌患者的临床管理和治疗。
Zotero 插件
